Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology company that is reshaping the landscape of cancer treatment through its proprietary INTASYL siRNA gene silencing technology. As a company focused on immuno-oncology therapeutics, Phio is dedicated to improving the ability of the body’s immune cells to target and eliminate tumor cells. Backed by rigorous scientific research and collaborative partnerships with leading research institutions, the company is committed to advancing next-generation treatments that address the immune suppression often induced by tumors.
Core Technology and Therapeutic Approach
The cornerstone of Phio Pharmaceuticals’ approach is its INTASYL platform, a unique self-delivering RNAi technology that bypasses the conventional need for specialized drug delivery systems. Unlike other RNAi therapies, INTASYL can target virtually any gene with high specificity, ensuring that immune cells are better equipped to kill cancer cells without impacting non-harmful cells. This innovative technology is specifically designed to silence genes responsible for tumor-induced immune suppression, thereby enhancing the efficacy of adoptive cell therapy as well as other immuno-oncology treatments.
Clinical-Stage Programs and Product Pipeline
Phio’s product development strategy centers on a portfolio of therapeutics that leverage INTASYL to selectively silence key checkpoint proteins. Its lead clinical program, PH-762, is an INTASYL compound aimed at silencing PD-1, a protein that inhibits the immune response by dampening T cell activity. This approach offers a potential non-surgical treatment option for various skin cancers such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. In addition, the company is developing other compounds, including ones that target TIGIT and PD-L1, to broaden its impact in the immuno-oncology space.
The ongoing Phase 1b clinical trials utilize an intratumoral injection strategy, which not only provides localized treatment but also enhances the immune system's ability to combat tumors systemically. The safety and efficacy profiles observed in early cohorts underscore the potential of Phio’s approach, with early clinical data emphasizing tumor clearance in patients while maintaining a manageable safety profile.
Scientific Collaborations and Research Excellence
Phio Pharmaceuticals collaborates with renowned institutions across the globe, including partnerships with collaborative research centers and academic institutions. These collaborations, with entities like Gustave Roussy, Medigene AG, and Helmholtz Zentrum, underscore the company’s commitment to scientific excellence and innovation. Working jointly with experts in immunology and oncology, Phio benefits from access to advanced research methodologies and clinical expertise, further solidifying its position as an innovator in the RNAi and immuno-oncology domains.
Market Position and Competitive Landscape
Operating within the competitive realm of biotechnology and cancer therapeutics, Phio Pharmaceuticals distinguishes itself by leveraging a novel technology platform that integrates precision medicine with the power of the immune system. The ability of the INTASYL platform to effectively silence genes without the need for extensive formulation upgrades positions the company uniquely amongst peers and potential collaborators. This technological edge is particularly significant in the context of adoptive cell therapy, where streamlined delivery and strong gene specificity are critical for success.
Technological Advantages of INTASYL
The INTASYL siRNA technology offers several key advantages:
- Self-Delivery: Eliminates the need for complex delivery vehicles, reducing development hurdles and potential complications.
- High Specificity: Capable of silencing target genes with a high degree of precision across a wide range of cell types, thereby mitigating off-target effects.
- Versatility: The platform’s ability to target virtually any gene affords tremendous flexibility in addressing various pathways associated with tumor immune suppression.
- Enhanced Immune Function: By targeting immunosuppressive proteins, Phio’s therapies aim to activate and bolster the body's natural defenses against cancer cells.
Understanding the Business Model
Phio Pharmaceuticals generates value by advancing its clinical-stage pipeline through strategic investments in research and development, clinical trials, and collaborations with academic and research centers. While the company is primarily in the research and development phase, its focus on breakthrough technologies and innovative therapeutic approaches forms the backbone of its long-term strategy. By maintaining a diversified pipeline that targets multiple immune regulatory pathways, Phio effectively manages scientific risk while paving the way for potential future therapies that address the multifaceted challenges of cancer treatment.
Commitment to Scientific Rigor and Transparency
In its quest to provide a thorough understanding of its technologies and clinical developments, Phio Pharmaceuticals embraces a transparent approach to research and data reporting. The company regularly presents data at industry conferences and in peer-reviewed journals, thereby contributing to the broader scientific community’s understanding of RNAi and immuno-oncology. This commitment to transparency not only enhances its credibility among investors and researchers but also underscores the company’s dedication to advancing scientific knowledge in a challenging and dynamic field.
Conclusion
Phio Pharmaceuticals Corp stands at the intersection of innovation and clinical research, leveraging a unique self-delivering RNAi technology to address the unmet needs in cancer therapy. Its comprehensive approach, which combines precision gene silencing with enhanced immune cell activity, positions it as a notable participant in the biotechnology arena. By continuously advancing its clinical programs and forging strategic collaborations, Phio demonstrates a firm commitment to improving patient outcomes through cutting-edge science and technology.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $1.83 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 610,000 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 1,220,000 shares of common stock at an exercise price of $3.00 per share, exercisable upon issuance and expiring in 24 months.
The offering, expected to close around January 17, 2025, is being exclusively placed by H.C. Wainwright & Co. The net proceeds will be used for working capital and general corporate purposes. The common stock shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 833,335 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 1,666,670 shares of common stock with an exercise price of $3.00 per share, exercisable upon issuance and expiring in 24 months.
H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around January 15, 2025. The company plans to use the net proceeds for working capital and general corporate purposes. The common stock shares are being offered through a shelf registration statement, while the warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $3.19 million registered direct offering priced at-the-market. The company will sell 1,063,670 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 2,127,340 shares of common stock at an exercise price of $3.00 per share, exercisable upon issuance with a 24-month expiration.
The offering, expected to close around January 15, 2025, is being conducted with H.C. Wainwright & Co. as the exclusive placement agent. Phio intends to use the net proceeds for working capital and general corporate purposes. The common shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive results from the second cohort of its Phase 1b clinical study of PH-762. The study evaluates the safety and tolerability of intratumoral PH-762 in various skin cancers. Two patients with cutaneous squamous cell carcinoma achieved complete response (100% tumor clearance) at Day 36. Among other patients in the second cohort, one showed partial response (90% tumor clearance) and another had stable disease.
The trial included 7 patients total, with 6 diagnosed with cutaneous squamous cell carcinoma and 1 with metastatic melanoma. Importantly, no dose-limiting toxicities or clinically relevant treatment-emergent adverse events were reported, and the intratumoral injections were well tolerated. The study continues to enroll patients to assess higher dose concentrations of PH-762.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of research on RXI-231, an INTASYL compound designed to treat hyperpigmentation, in Clinical, Cosmetic and Investigational Dermatology's December 2024 issue. The study demonstrates that RXI-231 effectively reduces tyrosinase (TYR) gene expression and melanin content in human melanocytes and 3D epidermal cultures.
The research shows that applying RXI-231 every other day visibly reduced pigmentation in 3D epidermal cultures. Testing using the MatTek EpiDerm Skin Irritation model confirmed the compound's non-irritant profile. While additional clinical testing is required, RXI-231 shows promise for treating hyperpigmentation disorders.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a registered direct offering of 240,000 shares of common stock priced at $2.00 per share, expected to raise $0.48 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules. Additionally, the company will issue unregistered warrants to purchase up to 240,000 shares with an exercise price of $2.00 per share, exercisable upon issuance and expiring in five years. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around December 24, 2024, with proceeds intended for working capital and general corporate purposes.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 437,192 shares of common stock at $2.635 per share, along with unregistered warrants to purchase an equal number of shares at $2.51 per share in a concurrent private placement. The warrants will be exercisable upon issuance and expire after five years.
H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is expected to close around December 20, 2024. Phio plans to use the net proceeds for working capital and general corporate purposes. The common stock offering is made under an effective S-3 shelf registration, while the warrants are issued through a private placement under Section 4(a)(2) of the Securities Act.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive results from the second cohort of its Phase 1b clinical trial evaluating PH-762 for treating various skin cancers. The Safety Monitoring Committee (SMC) recommended proceeding to the third dose cohort following encouraging safety data. The second cohort, comprising 4 patients with cutaneous squamous cell carcinoma, showed promising results with the first two patients achieving complete response (100% tumor clearance) and partial response (90% clearance) at Day 36. The intratumoral injections were well-tolerated with no dose-limiting toxicities or serious adverse events reported.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of their research on PH-762, their INTASYL® siRNA compound, in Frontiers in Immunology. The article presents preclinical proof-of-concept data for PH-762, designed to silence PD-1 for cancer treatment. Recent Phase 1b clinical trial data showed promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in cutaneous squamous cell carcinoma treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) has been nominated as a finalist for the Technology Disruptor of the Year award at Advanced Therapies Week 2025 in Dallas. The nomination highlights their patented INTASYL technology, a siRNA gene silencing platform designed to enhance immune cells' cancer-fighting capabilities.
Recent clinical data from their Phase 1b study of INTASYL compound PH-762 showed promising results, with one cutaneous squamous cell carcinoma patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance). The award ceremony will take place January 20-23, 2025, featuring judges from H.C. Wainwright & Co., Gama Biosciences, and Propel Biosciences.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What is the primary focus of Phio Pharmaceuticals Corp?
How does the INTASYL technology work?
Which therapeutic targets are addressed by Phio's pipeline?
What clinical trials is Phio currently engaged in?
How does Phio position itself within the competitive biotech industry?
What are the advantages of the INTASYL platform?
Who are some of Phio's research collaborators?
What role does PH-762 play in Phio's clinical program?
